Studies Highlight a Revolutionary New Method of Treating Post-Operative Bruising

- Candela`s Vbeam Laser Gives Millions of Post-Surgical Patients a New Sense of
Freedom -
WAYLAND, Mass.--(Business Wire)--
Candela Corporation (NASDAQ: CLZR) announced today that two studies have
reported superior results on patients who benefited from the Candela Vbeam laser
treatments for bruising resulting from cosmetic procedures. The studies
concluded that the Vbeam pulsed-dye laser significantly expedited the healing
process, improved outcomes, and provided greater overall patient satisfaction.

A study published in the March/April 2009 edition of the Archives of Facial
Plastic Surgery,entitled: "Pulsed-Dye Laser for Treating Ecchymoses After Facial
Cosmetic Procedures" by DeFatta, R. J., Krishna, S., and Williams, E. F., III
concluded that "the Vbeam laser treatment resulted in a 63% mean improvement in
ecchymoses scores within forty-eight (48) to seventy-two (72) hours."

The second study, a 2009 ASLMS abstract, entitled: "A Simple Solution to a
Common Problem" evaluated the effectiveness and safety of the long-pulse PDL
(the Vbeam) for the treatment of ecchymoses. In this study by Elizabeth Hale,
M.D., Julie Karen, M.D., Chris Hunzeker, M.D., Elliot Weiss, M.D., Leonard
Bernstein, M.D., Lori Brightman, M.D., Anne Chapas, M.D., and Roy Geronemus,
M.D. results showed that twenty-four hours post-treatment with the Vbeam laser,
the average improvement was 62% and 13% for treated and untreated bruises,
respectively.

Edwin F. Williams, M.D., Director, The Williams Center Plastic Surgery
Specialists, and nationally recognized plastic surgeon pioneered this
breakthrough Vbeam treatment. "Anytime you penetrate the skin there is a
potential for bruising and we find that it is the bruising which occurs after
many of these procedures that prevents patients from getting out into the
public. It is extremely difficult to cover these unsightly marks with make-up
and bruising can last for a number of weeks," said Dr. Williams. Dr. Williams
continued, "After just one treatment with the Vbeam, our patients experience
dramatic clearance of the injured blood vessels. This treatment is a significant
differentiator to our practice and we are excited to finally be able to offer
our patients a safe and easy treatment of bruising that works!"

Roy G. Geronemus, M.D., Director, Laser & Skin Surgery Center of New York,
commented, "There are millions of surgical and injectable procedures performed
every year which often have bruising as a side effect that can last up to two
weeks." Dr. Geronemus continued, "This is a significant new use for the Vbeam
which was already our "workhorse" laser because of its efficacy and safety
profile for a wide variety of applications including skin rejuvenation, the
treatment of rosacea, acne, diffuse redness, scars and more."

For more information and to request copies of the studies, visit
www.candelalaser.com or call 800-733-8550, ext. 247.

About CANDELA: Candela Corporation manufactures and distributes innovative
clinical solutions that enable physicians, surgeons, and personal care
practitioners to treat selected cosmetic and medical conditions using lasers,
aesthetic laser systems, and other advanced technologies. Founded near Boston in
1970, Candela markets and services its products in 86 countries from offices and
distributors in the United States, Europe, Japan, China and other Asian
locations. Candela established the aesthetic laser market 20 years ago, and
currently has an installed base of over 14,000 systems worldwide. Visit Candela
on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein,
this news release contains forward-looking statements that constitute Candela
Corporation`s current intentions, hopes, beliefs, expectations or predictions of
the future, which are therefore inherently subject to risks and uncertainties.
These statements include declarations regarding our or our management`s beliefs
and current expectations. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "potential" or "continue" or
the negative of such terms or other comparable terminology. These
forward-looking statements are subject to inherent risks and uncertainties in
predicting future results and conditions that could cause the actual results to
differ materially from those projected in these forward-looking statements. The
risks and uncertainties that may affect forward-looking statements include,
among others: the availability of, and our ability to successfully implement
strategic and operational alternatives, the pendency of re-examinations of the
`844 Patent and the `568 Patent before the PTO, our alleged infringement of the
`844 Patent and the `568 Patent, the validity of the `844 Patent and the `568
Patent, our expected legal expenses, our exploration of strategic and
operational alternatives, the expected recovery of our industry, our future
revenue, gross margin, expense levels and earnings, our growth prospects, market
acceptance of our products, the strength of our distribution channels, our
ability to add new products, our ability to expand regulatory approvals and the
liquidity of our common stock, the cancellation or deferral of customer orders,
the risk of a material adverse judgment or increased litigation-related expenses
in pending litigation matters, dependence on a small number of strategic
distribution relationships, difficulties in the timely development and market
acceptance of new products, unanticipated increases in expenses, market
developments that vary from the current public expectations concerning the
growth of the laser industry, increased competitive pressures, changes in
economic conditions, or difficulties in obtaining timely regulatory approvals.
Further information on factors that could affect Candela's performance is
included in Candela's periodic reports filed with the SEC. Candela cautions
readers not to place undue reliance upon any such forward-looking statements,
which speak only as of the date made. Candela expressly disclaims any
obligations or undertaking to release publicly any updates or revisions to any
such statements to reflect any change in Candela's expectations or any change in
events, conditions or circumstances on which any such statement is based.

Candela Corporation
Jane Smith, 508-358-7400, x247
jane.smith@candelalaser.com

Copyright Business Wire 2009